KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Cash from Investing Activities (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Cash from Investing Activities data on record, last reported at -$94.9 million in Q3 2025.

  • For Q3 2025, Cash from Investing Activities fell 305.73% year-over-year to -$94.9 million; the TTM value through Sep 2025 reached $58.6 million, down 41.2%, while the annual FY2024 figure was $142.6 million, 2.15% up from the prior year.
  • Cash from Investing Activities reached -$94.9 million in Q3 2025 per NKTR's latest filing, down from $49.6 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $130.3 million in Q1 2022 and bottomed at -$94.9 million in Q3 2025.
  • Average Cash from Investing Activities over 5 years is $44.7 million, with a median of $43.7 million recorded in 2025.
  • Peak YoY movement for Cash from Investing Activities: soared 13521.08% in 2022, then crashed 305.73% in 2025.
  • A 5-year view of Cash from Investing Activities shows it stood at $120.2 million in 2021, then plummeted by 66.71% to $40.0 million in 2022, then plummeted by 56.56% to $17.4 million in 2023, then soared by 246.4% to $60.2 million in 2024, then crashed by 257.56% to -$94.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$94.9 million in Q3 2025, $49.6 million in Q2 2025, and $43.7 million in Q1 2025.